Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,154 | 151 | 99.5% |
| Education | $19.98 | 2 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Relypsa, Inc. | $611.52 | 12 | $0 (2020) |
| Vifor Pharma, Inc. | $446.30 | 19 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $402.40 | 15 | $0 (2022) |
| AKEBIA THERAPEUTICS INC | $329.96 | 16 | $0 (2022) |
| Aurinia Pharma U.S., Inc. | $322.38 | 15 | $0 (2022) |
| La Jolla Pharmaceutical Company | $252.77 | 4 | $0 (2019) |
| Fresenius USA Marketing, Inc. | $196.53 | 10 | $0 (2022) |
| Keryx Biopharmaceuticals, Inc. | $179.55 | 7 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $154.81 | 7 | $0 (2022) |
| OPKO Pharmaceuticals, LLC | $148.66 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $52.16 | 2 | NXSTAGE MEDICAL, INC. ($33.49) |
| 2023 | $13.60 | 1 | Calliditas Therapeutics US Inc. ($13.60) |
| 2022 | $1,286 | 56 | Vifor Pharma, Inc. ($314.15) |
| 2021 | $688.77 | 29 | Vifor Pharma, Inc. ($132.15) |
| 2020 | $244.48 | 12 | AKEBIA THERAPEUTICS INC ($105.46) |
| 2019 | $1,284 | 37 | Relypsa, Inc. ($308.72) |
| 2018 | $589.26 | 15 | Relypsa, Inc. ($261.27) |
| 2017 | $16.10 | 1 | Novartis Pharmaceuticals Corporation ($16.10) |
All Payment Transactions
153 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/18/2024 | NXSTAGE MEDICAL, INC. | NXSTAGE SYSTEM ONE (Device), LIBERTY SELECT CYCLER | Food and Beverage | In-kind items and services | $33.49 | General |
| Category: Nephrology | ||||||
| 09/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.67 | General |
| 11/16/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Education | Cash or cash equivalent | $13.60 | General |
| Category: Nephrology | ||||||
| 10/05/2022 | Vifor Pharma, Inc. | — | Education | In-kind items and services | $6.38 | General |
| 06/28/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.98 | General |
| Category: KRYSTEXXA | ||||||
| 06/27/2022 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $31.80 | General |
| Category: Hyperkalemia | ||||||
| 06/23/2022 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: Phosphate binder for ESRD | ||||||
| 06/22/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: NEPHROLOGY | ||||||
| 06/21/2022 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Immunosuppresant | ||||||
| 06/20/2022 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: Nephrology | ||||||
| 06/16/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $120.35 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 06/16/2022 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: Nephrology | ||||||
| 06/16/2022 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: IMMUNOLOGY | ||||||
| 06/15/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.97 | General |
| Category: KRYSTEXXA | ||||||
| 06/15/2022 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: NEPHROLOGY | ||||||
| 06/14/2022 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/03/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: NEPHROLOGY | ||||||
| 06/02/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 06/02/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $2.84 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 05/18/2022 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: IMMUNOLOGY | ||||||
| 05/17/2022 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: Hyperkalemia | ||||||
| 05/16/2022 | AKEBIA THERAPEUTICS INC | Auryxia (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Nephrology | ||||||
| 05/10/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: NEPHROLOGY | ||||||
| 05/05/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 05/04/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $3.20 | General |
| Category: LUPUS NEPHRITIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 661 | 2,119 | $490,967 | $208,029 |
| 2022 | 8 | 696 | 2,102 | $449,290 | $176,688 |
| 2021 | 8 | 545 | 1,575 | $347,085 | $139,349 |
| 2020 | 10 | 699 | 1,822 | $364,237 | $166,293 |
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 196 | 771 | $170,496 | $76,851 | 45.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 166 | 752 | $115,072 | $49,844 | 43.3% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 18 | 96 | $60,360 | $28,398 | 47.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 126 | 138 | $58,914 | $19,370 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 103 | 209 | $49,115 | $16,474 | 33.5% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 21 | 46 | $24,632 | $11,345 | 46.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 18 | 94 | $7,802 | $3,886 | 49.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,576 | $1,859 | 40.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 230 | 782 | $172,822 | $67,476 | 39.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 214 | 853 | $130,509 | $50,994 | 39.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 125 | 129 | $55,212 | $21,420 | 38.8% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 13 | 65 | $39,650 | $19,764 | 49.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 124 | $29,140 | $8,815 | 30.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 107 | $8,881 | $3,460 | 39.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 28 | 28 | $8,148 | $2,885 | 35.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,928 | $1,874 | 38.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 196 | 845 | $186,627 | $74,406 | 39.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 127 | 422 | $64,526 | $25,940 | 40.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 121 | 137 | $58,636 | $22,877 | 39.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 74 | $17,390 | $7,912 | 45.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 21 | 21 | $7,392 | $3,023 | 40.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 23 | 23 | $6,693 | $2,673 | 39.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 12 | 18 | $2,916 | $1,369 | 47.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 11 | 35 | $2,905 | $1,148 | 39.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 248 | 834 | $163,369 | $74,376 | 45.5% |
About Dr. Alan Cantillep, MD
Dr. Alan Cantillep, MD is a Nephrology healthcare provider based in Fountain Valley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2013. The National Provider Identifier (NPI) number assigned to this provider is 1639517808.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Cantillep, MD has received a total of $4,174 in payments from pharmaceutical and medical device companies, with $52.16 received in 2024. These payments were reported across 153 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($4,154).
As a Medicare-enrolled provider, Cantillep has provided services to 2,601 Medicare beneficiaries, totaling 7,618 services with total Medicare billing of $690,358. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Fountain Valley, CA
- Active Since 06/11/2013
- Last Updated 01/16/2026
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639517808
Products in Payments
- Veltassa (Drug) $980.99
- JYNARQUE (Drug) $402.40
- LUPKYNIS (Drug) $322.38
- Auryxia (Drug) $282.64
- GIAPREZA (Drug) $252.77
- AURYXIA (Drug) $226.87
- ACTHAR (Biological) $204.86
- Velphoro (Drug) $176.53
- Kerendia (Drug) $154.81
- Envarsus (Drug) $145.96
- GENERAL VASCULAR INTERVENTION (Device) $118.02
- KRYSTEXXA (Biological) $112.94
- Parsabiv (Drug) $112.32
- Rayaldee (Drug) $82.68
- Renal - PD (Device) $72.15
- RAYALDEE (Drug) $65.98
- TARPEYO (Drug) $65.98
- Parsabiv (Biological) $34.76
- NXSTAGE SYSTEM ONE (Device) $33.49
- INJECTAFER (Drug) $24.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Fountain Valley
Dr. Ajit Sawhney, M.d, M.D
Nephrology — Payments: $205,530
Rallabhandi Sankaram, M.d, M.D
Nephrology — Payments: $6,738
Thanh Cao, D.o, D.O
Nephrology — Payments: $6,424
Dr. Sajeet Sawhney, M.d, M.D
Nephrology — Payments: $6,179
Dr. Zavier Ahmed, M.d, M.D
Nephrology — Payments: $1,799
Dr. Sandeep Dang, M.d, M.D
Nephrology — Payments: $1,606